found that A9 (B8) conferred EGFR-TKI-mediated antitumor effects in NSCLC cells with IC50 values of 0.22 nM and 0.25 nM against human and murine ADAM17, respectively (261). The gene discussed is ADAM17; the disease is non-small cell lung carcinoma.